A bladder-neck opening test using alfuzosin, a new alpha-adrenoceptor blocking agent, was carried out in 21 patients with spinal cord injury. The efficacy of alJuzo sin was assessed with 4 simple urodynamic parameters: micturition, residual urine, posterior urethral pressure and diameter. Both mean urethral pressure and diameter were significantly affected after the administration of 5 mg i.v. alJuzosin. The test was clinically positive in 18 patients: 11 out of 13 patients using intermittent cath eterisation or continuous drainage urinated and 6 out of 8 patients already tapping had reduced residual urine volumes. A decrease in posterior urethral pressure was also observed in 2 out of 3 patients who did not respond clinically to alJuzosin.
During spinal shock following spinal cord injury, urethral profile actiVIty is stable but remains static throughout bladder filling (Awad et al., 1977) , regard less of the site of injury (McGuire et al., 1977; Rossier and Ott, 1976) . Later, when a reflex activity has appeared below the site of the lesion, even though the pattern of dysfunction varies with the site and extent of the lesion, the incidence of inappropriate urethral resistance is high, irrespective of the site of the injury (Buzelin and Labat, 1984; McGuire et al., 1977; Scott and Morrow, 1978) .
Bladder neck and urethral smooth-muscle sphincter have been reported to be mainly supplied by adrenergic nerves and are essentially provided with alpha-l adrenergic receptors (Gosling et al., 1977; McGuire, 1986) . Earlier studies have shown the beneficial effect of alpha-blockers in patients with neurogenic bladder voiding dysfunction (Awad et al., 1977; Buzelin et al., 1984; Tulloch and Ros sier, 1977) . Alfuzosin is a new alpha-blocker with a high degree of selectivity for alpha-l-adrenoceptors (Cavero et al., 1984 (Cavero et al., , 1985 . The drug is available in i.v. and oral formulations.
This study was designed to evaluate the effect of one does of i. v. alfuzosin on micturition in patients with spinal cord injury in order to predict the potential efficacy of the oral formulation. The results of this test might also help in the understanding of the mechanism of the vesico-sphincteral dysfunction.
Patients and m.ethods
The study was performed in 21 patients, 6 women and 15 men (mean age 31.6 ± 3.8 years, range 17-68 years). Two patients had incomplete tetraplegia. Nineteen patients were paraplegic; lesions were complete in 13 patients and incomplete in the remaining 6. All but 3 had experienced spinal cord injury for more than 3 months.
Evaluation of the vesical and urethral dysfunction was made according to clinical neurological assessments, intravesical and posterior urethral pressure recordings, cystography and urethral sphincter electromyography; the latter pa rameter was evaluated independently from pressure recordings. In all but 3 pa tients, the pattern of lower urinary tract dysfunction was reflex. The external urethral sphincter was hypertonic in 5 patients, but dyssynergic in only 1 of them. The detrusor was hypotonic or flaccid in 11 patients. In 10 patients intermittent catheterisation was used to empty their bladder and 3 patients had continuous catheter drainage. Eight patients were already tapping.
The pharmacological test itself was carried out as follows: 10 patients with hypotonic or flaccid detrusor received subcutaneous bethanechol chloride (0.5 mg/l0 kg), a parasympathomimetic agent, prior to the administration of alfuzosin in order to reinforce bladder voiding pressure (Buzelin et at., 1984) ; 5 mg of alfuzosin was administered intravenously, over 20 minutes, using an electric infusion pump. Chart recordings of bladder and intra-urethral pressures were obtained using a Buselin two-way catheter and an electronic microtrans ducer connected to a two-way Hewlett Packard recorder (infusion rate 15 ml/ min, paper speed: 20 mm/min). Posterior urethral pressure was measured half way between the bladder neck and the external sphincter; the localisation of the catheter was checked using X-rays. In all cases, the largest pressure drop was considered. Instantaneous micturitional X-rays enabled the vesico-urethral junc tion to be visualised and the urethral diameter to be measured. An X-ray index was used to measure urethral diameter ( Figure) and urethral pressure was meas ured under the same conditions before and after administration of alfuzosin. Bladder filling was stopped just before the infusion of the drug, in order to maintain a steady volume. Intravesical pressure was checked simultaneously using the two-way catheter and monitored with the bladder X-ray picture. Bladder neck opening was visualised on instantaneous X-ray pictures, before and after administration of alfuzosin, at the maximum of bladder pressure rise following suprapubic tapping. In all cases, measurements were repeated twice.
The test was considered to be fully positive if suprapubic tapping was fol lowed by micturition in less than 5 minutes in the patients using intermittent catheterisation or continuous drainage. In the patients already tapping, posi tivity was linked to a clear decrease in residual urine (less than 30% of the voided volume after the test). Heart rate and blood pressure were monitored during the test. Fully written informed consent was obtained from each patient. Comparison of data before and after the administration of alfuzosin was made using a t-test for matched pairs. The reported p levels are for two-tailed tests.
Results
Complete or incomplete micturition occurred in 12 out of the 13 patients who did not urinate before. Among the 8 patients already tapping, 5 patients had clearly reduced residual volumes and 1 patient with no residual urine before the test had a much easier micturition. Altogether, 18 out of 21 patients responded clinically to alfuzosin.
Mean changes in urodynamic parameters are reported in Table I : both posterior urethral pressure and bladder-neck opening (urethral diameter) were significantly affected after the administration of alfuzosin. The mean posterior urethral pres sure fell from 27.7 to 12.4 cm H20 and the mean urethral diameter increased from 3.9 to 10.6 mm. Detrusor pressure was not significantly reduced after alfuzosin (data not shown) as previously reported by others with prazosin (Jensen, 1981a) .
Three patients failed to respond clinically to alfuzosin. Their individual uro dynamic data are given in Table II : patients 12 and 21 had a significant drop in urethral pressure; patient 21 also had a clear increase in urethral diameter. Patient 16 did not have significant changes in any of the 2 urodynamic parameters. Alfuzosin was well tolerated during the test. One patient complained of feeling cold. Only 2 episodes of moderate tachycardia and 1 case of hypotension (lOS/50 mmHg versus 125/75 mmHg prior alfuzosin) were reported during the test. The effect of alfuzosin on heart rate and blood pressure is shown in Table III .
Discussion
This test, reliable because of its simplicity and reproducibility, assessed the effect of 5 mg i.v. of alfuzosin, a new alpha-blocking agent, on 4 simple uro dynamic parameters (micturition, residual urine, posterior urethral pressure and diameter). This was performed in 21 patients with neurogenic lower urinary tract dysfunction. The overall results of the test were positive in 20 patients since a partial response with a decrease in posterior urethral pressure was also observed in 2 out of 3 patients who did not respond clinically to the administra tion of alfuzosin. However the quality of the response varied between patients. This can be explained, not only by the extent of outflow resistance and intensity of the alpha-blocking effect, but also by the detrusor contractility. The detrusor function itself varies with the site of the lesion and the time elapsed since the injury (McGuire et ai., 1977) . Therefore, this test should not be performed until at least 6 months after the injury, when detrusor activity has stabilised. The overall positive results of this test confirmed the increased sympathetic tone of the posterior urethra in the majority of patients with spinal cord injury (McGuire et ai., 1977) and the alpha-blocking activity of alfuzosin on posterior urethral pressure and diameter, and similarly, the predominant adrenergic supply of this part of the lower urinary tract. With the patients having a poor response to alfuzosin because of an inadequate bladder contractility, X-rays showed a widening of the junction only at the level of the posterior urethral portion and not above, thus suggesting a lack of involvement of the bladder fibres of the junction in the pharmacological response (Figure) . These results are in agreement with the findings of Gosling who reported a sparse distribution of adrenergic nerves in the bladder neck (Gosling et ai., 1977) but somewhat opposed to the finding of others (Ek et ai., 1977; Sundin et ai., 1977) .
In the patients with a good response to the test, i.e. micturition with an efficient voiding and little residual urine, oral alfuzosin could be proposed as a mid-or long term medication, whereas it might not be recommended to patients with a weak or negative response to the test. Patients with a poor bladder contractility should use intermittent catheterisation and those with an efficient voiding pressure, therefore at risk of renal destruction, should have urethro scopy and probably sphincterotomy (McGuire, 1986) .
Although pharmacological blockade of the sympathetically innervated blad der neck has already been achieved with other alpha-blocking agents (Jensen, 1981 a; Scott and Morrow, 1978) alfuzosin seems of particular interest. Indeed, the availability of two formulations may make it possible to carry out such an i.v. test and to continue with the oral medication in the patients who have given a satisfactory response to this test. Further studies will be required to determine if the oral formulation can produce similar effects and which is the appropriate dosage. In this study, alfuzosin has also shown significant efficacy together with very few and minor adverse reactions.
